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The objective is to understand what really drives prescription expenditure at the end of life in order to
inform future expenditure projections and service planning. To achieve this objective an empirical
analysis of public medication expenditure on the older population (individuals  70 years of age) in
Ireland (n ¼ 231,780) was undertaken. A two part model is used to analysis the individual effects of age,
proximity to death (PTD) and morbidity using individual patient-level data from administrative phar-
macy records for 2006e2009 covering the population of community medication users. Decedents
(n ¼ 14,084) consistently use more medications and incur larger expenditures than similar survivors,
especially in the last 6 months of life. The data show a positive and statistically signiﬁcant impact of PTD
on prescribing expenditures with minimal effect for age alone even accounting for patient morbidities.
Nevertheless improved measures of morbidity are required to fully test the hypothesis that age and PTD
are proxies for morbidity. The evidence presented refutes age as a driver of prescription expenditure and
highlights the importance of accounting for mortality in future expenditure projections.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction and background
Growth in healthcare expenditures and in particular, prescribing
expenditures increases pressure on government budgets, health-
care providers and individuals. Understanding drivers of this
growth should enable forecasting of more accurate future expen-
ditures and inform appropriate policies to reduce expenditures.
Studies frequently associate ageingwith higher health care costs
relative to the younger population (Anderson and Hussey, 2000;
Gregersen, 2014; Miller, 2001; Reinhardt, 2000; Westerhout,
2006). The elderly population is estimated to cost between 30%
and 50% of total health care expenditure in OECD countries
(Jacobzone, 2002). Anderson and Hussey (2000) examined health
care expenditure and income across eight industrial countries and
estimated that the average person aged 65 years or more costs
between 2.7 and 4.8 times more than the average person aged
0e64 years.dy of Ageing (TILDA), Trinity
Ltd. This is an open access article uIn 2009 Ireland had a predominantly urban population of
approximately 4.4 million of which 0.34 million (7.6%) were 70
years or older (CSO, 2013). Similar to other developed countries the
Irish population over 70 years of age is predicted to almost double
by 2031 along with increases in the age dependency ratio (CSO,
2013). Coinciding with the beginnings of this demographic shift
Ireland has witnessed a large increase in public pharmaceutical
expenditures with annual growth in real per capita expenditure on
pharmaceuticals at 8.5% in the decade to 2009 (OECD average 3.5%)
(OECD, 2011) and an economic recession beginning in 2008. At the
time of this study those aged 70 years or older had access to free
medications (A co-payment was introduced in 2010, this is
currently V2.50 per item up to a maximum of V20 per family per
month in 2016). The over 70s accounted for 49.6% of the annual
public expenditure on prescription medication (Primary Care
Reimbursement Service (PCRS), 2010).
While ageing is frequently associated with higher health care
costs (Dormont et al., 2006) some commentators fail to acknowledge
that part of these higher costs reﬂect the greater number of people
close to death in this age group as well as age related health care
needs. Individuals health care needs are higher as they approach
death, with more than a quarter of all acute health care costsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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However individuals in their last year of life may not necessarily be
the oldest. There appears to be general consensus that PTD has an
effect on healthcare expenditures in acute and long term health care
(Comas-Herrera et al., 2007; McGrail et al., 2000; Payne et al., 2007;
Seshamani and Gray, 2004b; Werblow et al., 2007; Zweifel et al.,
1999). What is less known is the extent of the effect. Previous
studies have focused on hospital or long term care expenditures
with little separate analysis of medication expenditures. Wanless
(2002) highlighted the need to consider all healthcare utilisation
in relation to age, proximity to death and other factors.
The literature proposes three main possibilities on ageing and
health, all assume increasing longevity, Gruenberg's (1977) “Failure
of success” theory envisages the proportion of life spent in ill health
increasing as longevity increases, an expansion of morbidity. In
contrast to this Fries (1980) “compression of morbidity” theory
proposes that people will live longer healthier lives with a limited
period of illness at the end of life. A third possibility is put forward
by Manton (1982), who found the other two theories inadequate to
explain mortality trends in the USA. His hypothesis is of a “dynamic
equilibrium” where morbidity increases due to rising levels of
chronic conditions and disabilities amongst the older population
while serious disability would decrease. Morbidity would seem an
important component of any examination of PTD, although disen-
tangling the two in the last years of life may not be possible.
While attempts have been made to predict future expenditure
on prescriptions (Bennett et al., 2009) there currently appears to be
few studies on the impact of ageing on future drug expenditure
taking proximity to death into account (Kildemoes et al., 2006;
Seshamani and Gray, 2004c). The aim of this study is to examine
the importance of proximity to death, ageing and morbidity for
public expenditure on prescription medication and report the im-
plications for expenditure projections. Given the rising volume and
costs of prescribing experienced in developed countries, gaining an
understanding of what effects health care expenditure in this area
will assist policy makers to more accurately predict and develop
new policies to control future spending on prescription drugs.
2. Data and methods
2.1. Data
Community prescribing for 2006e2009 inclusive and mortality
data from 2009 to 2012 for individuals aged 70 years or more in the
Republic of Ireland were extracted from the Health Service Exec-
utive Primary Care Reimbursement Service (HSE-PCRS). This time
period was used to guarantee a full 36 months of observations for
decedents and to ensure the comparison survivors are not in their
last three years of life. The prescription dispensing data contain
records of all medications dispensed to individuals in the com-
munity. It does not include medicines that are only prescribed in
hospital, such as chemotherapy agents but it does include medi-
cations which may be initiated in hospital but continued in the
community such as anti-rejection drugs for transplant patients,
immunostimulants, medicines used in conjunction with chemo-
therapy or hormonal therapy. The following variables were
extracted: a unique person identiﬁer; date of birth; region, gender;
age; date of claim; details of medication dispensed and ingredient
cost. The ingredient cost is the ex-factory price plus the wholesale
mark-up and is the price negotiated for all regions between the
state health agency (The Health Service Executive HSE) and man-
ufacturers. Ingredient cost is the amount reimbursed to pharma-
cists for medications dispensed but does not include a dispensing
fee which varies based on overall quantities dispensed by an indi-
vidual pharmacy, the time of day and nature of the medication. Thelinked mortality records include a unique person identiﬁer and the
date of death. Unlike previous studies examining Health Care
Expenditure (HCE) which employed samples, the time period of
this study has been selected to facilitate the use of a national cohort.
In order to gain an insight into the differences between de-
cedents and survivors a matched case-control study methodology
was used. Decedents (cases) aged at least 72 years at the start of
2009 were selected to ensure they had access to freemedication for
the duration of the expenditure study 2006e2009, and were
matched 1:1 based on age, gender and region to survivors (con-
trols). Previous research has suggested that there may be regional
and gender variances in health service use (Conway et al., 2014;
Wren, 2011). Appendix Fig. A1 shows a participant ﬂowchart.
[INSERT LINK TO ONLINE APPENDIX] Controls (survivors) are those
individuals whowere in receipt of medication in 2009 and who did
not die in the subsequent three years (2010e2012). A descriptive
analysis of the monthly expenditures of both cases and controls
was undertaken and the mean monthly expenditures and medi-
cation usage of survivors and decedents were compared.
To provide more detailed information regarding the health and
social circumstances of the community dwelling population aged 70
or more which was not available from prescribing records data from
the Irish Longitudinal Study of Ageing (TILDA) was used. The ﬁrst
wave of TILDA provides a cross section of nationally representative
health, social and economic data on the Irish population aged 50
years or more (n ¼ 8174) with 2307 participants aged 70 or more in
2009/2010 and its methodology is described in detail elsewhere
(Kenny et al., 2010; Barrett et al., 2011). All prevalence results from
TILDA were weighted using age, sex and educational attainment to
be representative of the total population using the 2011 Census.
In addition a number of population scenarios from the Central
Statistics Ofﬁce (CSO) online database Statbank (CSO, 2013) were
used, based on the 2011 Census population ﬁgures, to estimate
future population taking births, deaths and migration into account
(see Appendix for a brief description). All analysis were conducted
using Stata version 12 (Stata Corp., College Station, Texas). Ethical
approval was received for this study from the Health Policy and
Management Research Ethics Committee, Trinity College Dublin.
2.2. Model speciﬁcation
The primary outcome was monthly individual expenditure on
community prescription medication for a 36 month period ending
in 2009 (month of death in 2009 or matched month for survivors),
which is highly skewed with non-constant variance and a large
number of zeros. Methods employed must account for the skewed
distribution of the data and the large numbers of zeros (zero-
inﬂation) (Blough and Ramsey, 2000; Manning and Mullahy, 2001).
Based on the literature examining expenditure data a two part
model (TPM) using a Probit and generalized linear model (GLM)
was considered appropriate. The Probit was used to identify those
who had any expenditure and the GLM to model those positive
expenditures. The following Probit model was run to examine the
effects of age, gender, proximity to death and region on the prob-
ability of using medication in a given month.
PrðExpend:>0Þ ¼ fþ b1Aþ b2A2 þ b3AGþ b4Gþ b5D
þ
X35
t¼1
mtMt þ
X7
e¼1
εeRþ
X35
t¼1
gtMtD
Where A: individual age; A2: Age squared; AG: Age gender inter-
action; G: Male gender (1), Female (0); D: decedent (1); M: months
until death or censor; R: Region; Mt D: decedent-month interaction
term. To account for the nonlinearity of age an age squared variable
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The second part of the model is a random effects GLM which
facilitates the analysis of mean costs while allowing for the non-
normal distribution of the data and the longitudinal observations
for each individual. Themodel consists of a distribution function for
costs and a link function which describes the nature of the rela-
tionship of the covariates with the cost. The various GLMs were
assessed using the modiﬁed Parks test following Manning and
Mullahy (2001), Akaike Information Criteria (AIC) and normal
probability plots of deviance residuals to ascertain a suitable dis-
tribution function. While there is no one test for assessing an
appropriate link function the following three tests were run for
guidance: Pearson correlation test; Pregibon link test; a modiﬁed
Hosmer and Lemeshow test. The consistent result from these tests
was gamma distribution function and a log link.
GLMðExp Þ ¼ fþ b1 þ b2Aþ b3A2 þ b4AGþ b5Gþ b6D
þ
X35
t¼1
mtMt þ
X8
e¼1
εeRe þ
X35
t¼1
gtMtD
The use of a log link function in the GLM means the coefﬁcients
act multiplicatively on the mean, by taking the exponential they
can be expressed as the percentage increase in the mean monthly
medication expenditure per unit increase in the covariate (Barber
and Thompson, 2004).
2.3. Chronic disease score
The pharmacy claims database lacks information on diagnosis,
thus combinations of pharmaceutical therapies are used as proxies
for broad medical conditions. This methodology lacks speciﬁcity for
certain conditions as some medications may have a broad applica-
tion across a number of conditions or even off label use. Despite this
limitation the methodology has been validated in several settings
(Fishman et al., 2003; Gray et al., 2000; Maio et al., 2005;
Schneeweiss et al., 2002; Silwer and Lundborg, 2005) and previ-
ously used on Irish data (Naughton et al., 2006). The score was
calculated following the methodology ﬁrst employed by Von Korff
et al. (1992). The index used is a pharmaceutical based comorbidity
index, calculated from the sumof 20potential chronic disease groups
derived from dispensing data using Anatomical Therapeutic Chem-
ical (ATC) codes (Appendix Table A1 lists the medications and ATC
codes used). Individuals were assumed to have one of the diseases if
they received at least three consecutive prescriptions of amedication
representing a speciﬁc disease class in a 12 month period.
2.4. Projection models
Two projection methods were used: ﬁrstly traditional multi-
plicative models and secondly regression based projections, both of
which are discussed in the following sections. Past mortality rates
were used to project possible future trends (See Appendix Fig. A2).
2.4.1. Traditional models
Two traditional projection models of prescription cost estima-
tion were used based on the current level of drug use continuing.
Model 1, was calculated by assuming the rate of medication use
remains constant at the 2009 level, applying age-sex speciﬁc pre-
scribing rates and 2009 mean costs/individual to the total popu-
lation. For each age group and sex we multiplied the mean
expenditures by the projected population number to gain a total
expenditure ﬁgure.
Model two in addition to model one includes proximity to death
assuming the increasing mortality trend observed over the lastdecade will continue. This involves using mortality estimates
detailed in Fig. A2 to project the number of decedents per year.
Separate costs for decedents and survivors from the historical data
analysis were used to calculate the total expenditure. These mor-
tality projections were used with age-sex speciﬁc prescribing rates
and costs/individual in 2009 for survivors and decedents.
2.4.2. Regression based models
Regression based predictions are calculated using the sum of the
two part model outlined earlier, holding other variables at their
mean values. Predicted cost in the two-part model:
EðYjXÞ ¼ PðY>0jXÞEðYjY>0;XÞ
Where P(Y>0jX) is the probability of any cost being incurred (Part
1) and E(YjY>0, X) is the predicted cost conditional on incurring any
cost (Part 2). The last twelve months (1e12) were used in
conjunction with population projections outlined in the previous
section to calculate the projected expenditures.
3. Results
3.1. Descriptive statistics
The contextual data from TILDA shows that 92.2% (95% CI
91e93.3%) of those aged 70 or more had a medical card entitling
them to free medications and the vast majority had only a primary
education or none, 60.7% (95% CI 58.6e62.8%). The total population
aged 70 years or more in 2006 that was used in the prescribing
study and the population characteristics are set out in the Appendix
Table A2. A total of 14,084 decedents or cases were matched to
14,084 survivors or controls with 65 cases not matched, due to the
very small numbers of older people in certain regions. Those un-
matched cases had a mean age of 99.3 years (Standard error (SE)
0.33yrs), a last year of life mean expenditure ofV1715.9 (SEV172.2)
and a median expenditure of V1361.6 (SE V168.2). In all time pe-
riods examined, 12, 24 or 36 months before death, decedents
consistently show higher expenditures on medications than their
counterparts who survived (see Fig. 1). The pattern changes in the
last 12 months of life, during which decedents have a sustained
month on month increase until death. Table 1 shows the decedent
to survivor ratio for mean monthly expenditure in the last 12
months of life by gender and age group. The decedent to survivor
ratios for the average number of items used shows a similar pattern
1.5 overall, 1.5 for females, 1.6 for males. (details of the expenditure
amounts and means are contained in the Appendix, Tables A3 and
A5) There is a declining ratio in number of items with age in fe-
males while males have a U shaped trend, bottoming in the 80e84
year old age group (Appendix Table A3). The higher expenditures of
decedents are more evident in younger age groups and also persist
as far out as three years before death. (Results for the full 36months
are shown in Appendix Tables A4 and A6).
3.2. Medication use
The median number of items per month was 4, mean of 5.6 (SE
0.002) and a range of 0e181. Table A1 in the appendix shows the
prevalence of chronic conditions, based on the chronic disease
score with 52.6% of the study population reporting 3 or more
chronic diseases, rising to 72.2% for decedents. We see higher
incidence of each chronic condition amongst decedents except for
migraines, osteoporosis and rheumatological conditions. As ex-
pected chronic conditions are a signiﬁcant driver of prescription
expenditures, resulting in an average increase of 24% in expendi-
ture per month for each additional condition. Dementia is
Fig. 1. Total monthly expenditures for matched cohort.
Table 1
Mean monthly expenditure ratio (decedents/ survivors) by age group and gender.
Gender Age group Mean expenditure ratio
(Decedents
/Survivors)
Both All 1.8
female All ages 1.7
72e74 2.0
75e79 1.9
80e84 1.7
85e89 1.5
90þ 1.6
male All ages 1.9
72e74 2.2
75e79 1.9
80e84 1.7
85e89 1.9
90þ 2.0
Table A3 in Appendix reports the full detail of expenditures used to calculate the
ratios.
P.V. Moore et al. / Social Science & Medicine 184 (2017) 1e144responsible for the largest average increase in expenditure (78%).
Acid related conditions, diabetes, epilepsy, hyperlipidemia, COPD
and asthma are all associated with a 40% or more increase in
average expenditures compared to those who don't have the con-
ditions (results in Appendix Table A1).
3.3. Regression analysis
Table 2 sets out the summary results of a two part model for the
full 3 year period, with the Probit showing the probability of
expenditure on prescription medication and the GLM regression
the effect on monthly expenditure per individual with the listed
explanatory variables (full results in Appendix Table A7). An
interaction term with decedent was included for each month to
capture the proximity to death effect. Looking at the basic model in
Table 2, age appears to have a neutral effect on expenditures, while
decedents have on average 23.1% larger expenditures. An additionalchronic condition increases monthly expenditures an average of
32.2%, taking the other variables contribution into account.
Applying the regression model on only the last year before death
shows both effects of being a decedent and having an additional
chronic condition increase to 39.1% and 39.8% respectively (Results
shown in appendix). Monthly expenditures for individuals who are
dispensed a medication (part 2 of the model) show that decedents
have consistently higher expenditure than survivors in the last 12
months of life. There is a marked increasing trend in the last 6
months of life, culminating in the last month with decedents hav-
ing an expenditure that is 1.58 times more than survivors.
3.4. Expenditure projection
The traditional multiplier models are set out in the appendix for
various population growth scenarios. In all cases not accounting for
proximity to death in the models leads to signiﬁcant over-
estimation of costs, ranging from 1.22 times to 1.73 times over-
estimated costs depending on the age group and demographics. In
general there is less overestimation for older age groups. Table 3
shows the ratio of the model including PTD (model 1) to the
model excluding (model 2). Full expenditures for each year and
model are listed in Appendix Table A8.
Taking the ratio of excluding PTD to including PTD shows an
overestimation of between 1.27 and 1.58 times depending on the age
group and year (see Table 3). The models based on the predicted
values display a similar pattern as the traditional models albeit with
a slightly larger effect. The predicted expenditures for each year are
displayed in the Appendix Table A9 for decedents and survivors.
4. Discussion
We investigated the effect of PTD, age and morbidity on his-
torical community prescription expenditures and used this data to
project future expenditures examining the effect of excluding PTD
in their calculation. The analysis was carried out on a population
administration dataset. Data from the Irish Longitudinal Study of
Table 2
Two part model using a Probit followed by a Generalized linear model (GLM) of monthly prescribing expenditures assuming a Gamma distribution with a log link.
Covariates Probit GLM on positive expenditures
Basic modela Interactions modelb Basic modela Interactions modelb
Coeff. Std. error b Std. error Coeff. Std. error b Std. error
Age 0.132ɸ 0.008 0.132ɸ 0.008 1.007 0.007 1.007 0.007
Age square 0.001ɸ 4.7  104 0.001ɸ 0.000 1.000 4.7  105 1.000 0.000
Male 1 1 1 1
Female 0.023ɸ 0.003 0.023ɸ 0.003 0.916ɸ 0.003 0.916ɸ 0.003
No. Chronic conditions 0.181ɸ 0.007 0.471ɸ 0.013 1.231ɸ 0.008 1.152ɸ 0.014
Decedents 0.277ɸ 0.001 0.278ɸ 0.001 1.322ɸ 0.001 1.322ɸ 0.001
AIC 11.385 11.384
Loglikelihood 37,628,213 37,625,078
ɸ Indicates signiﬁcance at the 99% level, respectively based on Z statistic.
Table A7 in Appendix reports the full detail of interactions and covariates used.
a Basic model includes dummy variables for 35 months prior to death/censor with month 36 as baseline and eight geographical regions with Midlands as the baseline.
b The interactions model additionally includes interactions between decedent and each month. Age and gender interactions where not signiﬁcant univariately and not
included in model.
Table 3
Ratio of Non PTD/ PTD (model 1/model 2) expenditures.
Model Age
(years)
2011 2016 2021 2026 2031
Traditional Model 1/2 70e74 1.52 1.53 1.53 1.54 1.54
Criteria: M3 75e79 1.41 1.41 1.42 1.43 1.44
Ratio: PTD/no PTD 80e84 1.29 1.30 1.31 1.32 1.33
85 and over 1.22 1.22 1.23 1.24 1.25
Predicted values from Two-part regression model 70e74 1.56 1.57 1.58 1.58 1.58
75e79 1.46 1.47 1.48 1.49 1.50
Criteria: M3 80e84 1.38 1.39 1.40 1.42 1.43
Ratio: PTD/no PTD 85 and over 1.27 1.28 1.29 1.30 1.32
Table A8 and A9 in Appendix report the full detail of expenditures used to calculate these ratios.Ageing (TILDA) conﬁrms that 92% of the population over 70 years
had access to publically funded medications in 2009/2010. Those
aged 70 or more account for 22.8% of the total number of in-
dividuals eligible for a medical card and 49.6% of the total pre-
scription drug expenditures in 2009 (Authors calculations based on
general medical card scheme data in (Primary Care Reimbursement
Service (PCRS), 2010).
The results of this study show that decedents, on average, use
more prescription medication and generate higher expenditures
than survivors as distant as three years before death. The effect of
PTD on prescription expenditures follows a similar trend to that of
acute hospital expenditures only, but with a lower magnitude.
Similar to acute hospital studies but in contrast to LTC studies age
hasminimal effect on expenditures.Whenwe attempt to account for
an individual's morbidities, PTD remains a predictor of prescribing
expenditure. Projection analysis shows the importance of taking
decedents into account when projecting future costs, failure to do so
will lead to an overestimation of expenditures, regardless of de-
mographic or projectionmodel chosen. This overestimation is due to
the higher expenditures of decedents increasing the total population
mean. Overestimation of expenditure was previously reported in a
Danish study but with a smaller effect (Kildemoes et al., 2006).
Similar to other studies we show a decline in the cost of dying
with age (Garattini and van de Vooren, 2013; Geue et al., 2014;
McGrail et al., 2000; Moore et al., 2014; Seshamani and Gray,
2004b) with those in the oldest group (90 years) costing on
average 1.3 times less than those in the youngest age group (72e74
years in 2009). The reason to focus on the last year of life in pro-
jection models follows from evidence in this study and others that
suggests this is when the PTD effect is the strongest (Smyth et al.,
2013; van Baal and Wong, 2012).
The step like increases in expenditures for survivors correspond
broadlywith changes in pricing contracts between the state and the
pharmaceutical industry. However Felder et al. (2010) posit thatincreasing medical technology may be responsible for increasing
healthcare expenditure (HCE). This is also a plausible explanation
for increasing pharmaceutical expenditures with high percentages
of individuals on relatively expensive preventative medications
introduced in the last decade and would explain the upward trend
in survivor expenditures evidenced in the data. For example we
know from TILDA data that 30.2% (95% CI: 29.1e31.2%) of the
population over 50 regularly take a statin (Statins are a medication
group used to lower cholesterol in the prevention of cardiovascular
disease and at the time of this study were relatively expensive, 28
tablets of 10 mg Atorvastatin being V66) which rises to 41.6% (95%
CI: 39.4e43.9%) of the population over 70 years and remains high in
the over 80 s at 38.8% (95% CI: 34.4e43.1%).
De Meijer et al. (de Meijer et al., 2011) using an individual level
Dutch dataset on LTC, found that once morbidity and disability
were controlled for PTD becomes insigniﬁcant while age remains a
driver of HCE. TILDA shows a prevalence of disability measured by
Activities of Daily Living (ADL) or Instrumental Activities of Daily
Living (IADL) impairment of 23% (95% CI 21.1e25%). With over a
ﬁfth of the population reporting a disability it makes it a plausible
contender which may explain increased levels of expenditure.
However we do not have individual level data on disability so we
cannot examine how this effected survivors and decedents. While
we did not control for disability, due to its absence from the pre-
scribing dataset, we have included dummy variables for 20 chronic
conditions, a chronic conditions count and based our study on
community prescribing and still found a strong PTD effect. A ﬂaw of
this method is an individual needs to have been dispensed a
medication for a condition before we can count it. They may have
conditions they do not know about or have not been prescribed a
medication for. The PTD effect that remains could be a proxy for
some other unobserved morbidity for frailty, disability or senes-
cence, all of which occur at different ages for different individuals
(van Deursen, 2014). Without detailed data on disabilities or frailty
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test any of these hypothesis.
The strength of this study lies in its use of a national population-
based cohort of prescribing data that is automatically collected at
the point of dispensing avoiding any recall or interview bias. We
also use actual expenditure data rather than estimates used by
other studies (Howdon and Rice, 2015; Seshamani and Gray,
2004a). A major limitation is the absence of linked morbidity and
disability data. We used a chronic conditions index based on
medications to try to overcome this limitation and discussed the
general characteristics of the population based on data from a large
cross-sectional study (TILDA). Similar to other studies we assumed
no endogeneity between PTD and medication expenditure. The
projections of future expenditure are based on observed patterns
which are likely to change due to new and improved preventative
and curative treatments, new pricing policies, patent expiries and
the lifestyle changes of individuals.5. Conclusion
The PTD effect is not just relevant for acute and LTC settings but
is also evident in community prescribing expenditures. While the
magnitude of the effect is lower than found in other settings it still
has an important impact on future expenditure projections. We
have shown that this effect is in part due to morbidity at the end of
life. We attempted to control for numerous morbidities which
demonstrated a reduction in the effect of PTD however we cannot
concretely conclude that the PTD effect is a proxy for morbidity. We
can conclude that based on the results age is not a driver of pre-
scription expenditure in the population age 70 years or more. We
need to obtain a greater understanding of what is driving this
increased prescribing expenditure for decedents, both for health
policy and for expenditure projections. Regardless of what age is a
proxy for, failure to account for the large number of individuals who
die in any year leads to an over estimation of the true expenditureFig. A1. Participanand perpetuates the theory of ageing alone driving costs.
Even including separate estimates for decedent and survivor
expenditures, as long as life expectancies increase there will be a
rise in the demand for medications in an ageing population. This
will be driven primarily by new products and the increasing
prevalence of chronic conditions. To fully address this issue a more
detailed dataset would be required. One that links prescribing data
to health care diagnostic and outcome measures would provide
more clarity on whether age is a proxy for proximity to death,
morbidity, disability, senescence or a combination of all four. As
people live longer with chronic conditions community based pre-
scription medication will become even more prevalent. This study
suggests that rather than focusing on ageing, policies aimed at
controlling costs for medications to treat chronic conditions and at
the end of life will help limit public expenditures.Acknowledgements
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Table A1
Chronic disease score e disease group composition
code Chronic disease Medications ATC codesa No. of
population
(%)
No. of
decedents
(%)
No. of
survivors
(%)
1 Acid related disorders Drugs for acid related disorders A02 87,545
(37.8)
8149
(57.9)
5346
(38.0)
2 Cancer Antineoplastic agents L01 624
(0.3)
79
(0.6)
41
(0.3)
3 Cardiovascular disease Digitalis glycosides, Antiarrhythmics, Organic nitrates C01 161,480
(69.7)
11,884
(84.4)
9699
(68.9)
Antihypertensives C02
Diuretics C03
Beta blockers C07
Calcium channel blockers C08
Agents acting on the renin-angiotensin system - ACE
inhibitors,
C09
Vitamin K antagonists B01AA
Platelet aggregation inhibitors (excluding Heparin) B01AC
4 Dementia Antidementia drugs N06D 9400
(4.1)
1470 (10.4) 719
(5.1)
5 Diabetes mellitus Insulins and analogs, Blood glucose lowering drugs, Other
drugs used in diabetes
A10 22,332
(9.6)
1871
(13.3)
1205
(8.6)
6 Epilepsy Antiepileptics N03 12,920
(5.6)
1470
(10.4)
712
(5.1)
7 Glaucoma Anti-Glaucoma and miotics S01E 14,399
(6.2)
959
(6.8)
1050
(7.5)
8 Gout and hyperuricemia Antigout preparations M04A 7707
(3.3)
801
(5.7)
461
(3.3)
9 Human Immunodeﬁciency
Virus (HIV)b
Protease inhibitors J05AE e e e
Non-nucleoside reverse transcriptase inhibitors J05AG
Antivirals for HIV J05AR
10 Hyperlipidemia Lipid lowering agents C10 106,585
(46)
5159
(36.6)
5598
(39.8)
11 Intestinal inﬂammatory
disease
Intestinal inﬂammatory agents A07E 1968
(0.9)
154
(1.1)
100
(0.7)
12 Iron deﬁciency anemia Iron preparations B03A 16,722
(7.2)
2449
(17.4)
1107
(7.9)
13 Migraines Antimigraine preparations N02C 321
(0.1)
14
(0.1)
12
(0.1)
14 Osteoporosis Drugs for treatment of bone diseases M05 34,263
(14.8)
2074
(14.7)
1890
(13.4)
15 Parkinson's disease Anti-Parkinson's drugs N04 5323
(2.3)
755
(5.4)
311
(2.2)
16 Psychiatric disorders Antipsychotics N05A 44,703
(19.3)
5350
(38.0)
2654
(18.9)
Psychoanaleptics N06A
17 COPD & Asthma Drugs for obstructive airways diseases R03 35,309
(15.2)
4017
(28.5)
1986
(14.1)
18 Rheumatological conditions Antirheumatic products M01AB, M01AC, M01AE,
M01AG, M01AH,
M01AX, M01CB, M01CC, P01BA
41,721
(18.0)
2318
(16.5)
2273
(16.2)
19 Thyroid disorders Thyroid therapy H03 24,354
(10.5)
1611
(11.4)
1299
(9.2)
20 Tuberculosisb Drugs for treatment of Tuberculosis J04A e e e
a All medications are described using WHO Anatomical Therapeutic Chemical (ATC) codes and names.
b There were no individuals with this condition.
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Table A2
Population characteristics at baseline (2009).
Total cohort population 2009 matched decedents 2009 matched survivors
N % N % N %
Total 231,710 100.0 14,084 6.1 14,084 6.1
Female 136,215 58.8 7539 53.5 7539 53.5
Mean Age 79.1 years 84.1 years 84.1 years
(SD) (5.5 years) (6.5 years) (6.5 years)
Male 95,495 41.2 6545 46.5 6545 46.5
Mean Age 77.9 years 81.6 years 81.6 years
(SD) (5.3 years) (5.9 years) (5.9 years)
Age Groups
72-74 63,120 27.2 1432 10.2 1432 10.2
75-79 82,158 35.5 3172 22.5 3172 22.5
80-84 51,973 22.4 3802 27.0 3802 27.0
85-89 25,120 10.8 3348 23.8 3348 23.8
90þ 9339 4.0 2330 16.6 2330 16.6
Region
Midlands 13,717 5.9 953 6.7 953 6.7
Mid-west 19,960 8.6 1433 10.2 1433 10.2
Northeast 19,851 8.6 1298 9.2 1298 9.2
Northwest 15,341 6.6 909 6.5 909 6.5
Southeast 28,324 12.2 1797 12.8 1797 12.8
South 36,936 15.9 2233 15.9 2233 15.9
West 27,033 11.7 1547 11.0 1547 11.0
East 70,548 30.5 3914 27.8 3914 27.8
Nr of chronic diseases
0 26,284 11.3 744 5.3 1690 12.0
1 34,434 14.9 1114 7.9 2058 14.6
2 49,143 21.2 2065 14.7 3008 21.4
3 121,849 52.6 10,161 72.2 7328 52.0
Table A3
Ingredient costs for 12 months prior to death or censored (1:1 matching on age, gender, region) for 2008/2009, decedents from 2009.
No. of
individuals
Total annual
expenditure
(V)
Mean expenditure per
individual
(V)
Median expenditure per
individual
(V)
Mean no. of items per
individual
Average expenditure per
prescription
(V)
(total no. Items)
Decedents All 14,084 29,667,717 2106.5 1722.0 107.5 19.6
female 7539 15,671,269 2078.7 1688.9 108.9 19.1
male 6545 13,996,448 2138.5 1761.0 105.8 20.2
Survivors All 14,084 16,622,139 1180.2 888.7 70.3 16.8
female 7539 9,262,681 1228.6 935.0 74.6 16.5
male 6545 7,359,458 1124.4 838.8 65.3 17.2
Table A4
Ingredient costs for 36 months prior to death or censored (1:1 exact matching on age (as at 1st Jan 2009), gender, region) for 2006e2009, decedents from 2009.
No. of
individuals
Total
expenditure
(SE)
(V)
Mean expenditure per
individual
(V)
Median expenditure per
individual
(V)
Mean no. of items per
individual
Average expenditure per
prescription
(V)
Decedents All 14,084 75,495,253 5360.4 4419.2 278.6 19.2
female 7539 40,262,621 5340.6 4417.8 285.0 18.7
male 6545 35,232,632 5383.1 4422.4 271.2 19.9
Survivors All 14,084 46,152,395 3276.9 2513.2 195.1 16.8
female 7539 25,632,571 3400.0 2635.2 206.6 16.5
male 6545 20,519,823 3135.2 2385.3 181.8 17.2
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Table A5
Ingredient costs for 12 months prior to death or censored (1:1 exact matching on age (as at 1st Jan 2009), gender, region), decedents from 2009 by age group and gender.
Age
group
Nr of
individuals
Total
expenditure
(V)
Mean expenditure per
individual
(V)
Median expenditure per
individual
(V)
Mean nr of items per
individual
Average expenditure per
prescription
(V)
Decedents
female
70e74 576 1,328,240 2306.0 1760.0 107.7 21.4
75e79 1415 3,329,458 2353.0 1940.6 112.5 20.9
80e84 1944 4,260,201 2191.5 1797.8 114.1 19.2
85e89 1953 3,956,046 2025.6 1687.5 110.0 18.4
90þ 1651 2,797,325 1694.3 1366.4 98.9 17.1
Decedents
male
70e74 856 2,011,561 2350.0 1913.5 106.9 22.0
75e79 1757 3,909,137 2224.9 1788.8 106.7 20.9
80e84 1858 3,938,596 2119.8 1807.5 106.2 20.0
85e89 1395 2,954,777 2118.1 1765.7 107.7 19.7
90þ 679 1,182,377 1741.4 1430.4 96.9 18.0
Survivors
female
70e74 576 651,539 1131.1 808.2 63.6 17.8
75e79 1415 1,749,202 1236.2 947.7 73.0 16.9
80e84 1944 2,556,039 1314.8 1001.5 78.4 16.8
85e89 1953 2,558,169 1309.9 995.5 79.6 16.4
90þ 1651 1,747,731 1058.6 771.1 69.3 15.3
Survivors
male
70e74 856 933,319 1090.3 747.4 58.9 18.5
75e79 1757 2,044,152 1163.4 880.9 64.7 18.0
80e84 1858 2,261,722 1217.3 944.6 71.8 16.9
85e89 1395 1,519,312 1089.1 827.9 65.9 16.5
90þ 679 600,952 885.1 603.9 55.8 15.8
Table A6
Ingredient costs for 36 months prior to death or censored (1:1 exact matching on age (as at 1st Jan 2009), gender, region), decedents from 2009 by age group and gender.
Age
group
No. of
individuals
Total
expenditure
(V)
Mean expenditure per
individual
(V)
Median expenditure per
individual
(V)
Mean no. of items per
individual
Average expenditure per
prescription
(V)
Decedents
female
70e74 576 3,252,414 5646.6 4386.7 270.8 20.8
75e79 1415 8,351,330 5902.0 4993.6 288.7 20.4
80e84 1944 11,026,979 5672.3 4661.2 298.9 19.0
85e89 1953 10,382,634 5316.2 4557.5 292.2 18.2
90þ 1651 7,249,264 4390.8 3666.6 261.9 16.8
Decedents
male
70e74 856 4,783,902 5588.7 4526.6 259.2 21.6
75e79 1757 9,826,965 5593.0 4556.1 270.9 20.6
80e84 1858 10,080,810 5425.6 4598.9 278.3 19.5
85e89 1395 7,568,999 5425.8 4447.0 280.8 19.3
90þ 680 2,971,955 4377.0 3618.3 247.8 17.7
Survivors
female
70e74 576 1,796,448 3118.8 2196.9 175.1 17.8
75e79 1415 4,808,147 3398.0 2595.8 201.1 16.9
80e84 1944 6,971,411 3586.1 2795.5 215.0 16.7
85e89 1953 7,125,596 3648.5 2880.3 220.8 16.5
90þ 1651 4,930,970 2986.7 2222.8 195.5 15.3
Survivors
male
70e74 856 2,561,955 2992.9 2103.6 161.0 18.6
75e79 1757 5,603,537 3189.3 2477.0 177.3 18.0
80e84 1858 6,383,478 3435.7 2644.8 201.4 17.1
85e89 1395 4,259,936 3053.7 2364.4 184.5 16.6
90þ 680 1,710,917 2519.8 1850.3 160.5 15.7
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Table A7
Two part model using a Probit followed by a Generalized linear model (GLM) of monthly prescribing expenditures assuming a Gamma distribution with a log link, for 36
months.
Covariates Probit GLM on positive expenditures
Basic model Interactions model Basic model Interactions model
Coeff. SE Coeff. SE Exp(Coeff.) SE Exp(Coeff.) SE
Age ***0.132 0.008 ***0.132 0.008 1.007 0.007 1.007 0.007
Age squared ***-0.001 4.7  104 ***-0.001 0.000 1.000 4.7  105 1.000 0.000
Male 1 1 1 1
Female ***0.023 0.003 ***0.023 0.003 ***0.916 0.003 ***0.916 0.003
No. Chronic conditions ***-0.181 0.007 ***-0.471 0.013 ***1.231 0.008 ***1.152 0.014
Decedents ***0.277 0.001 ***0.278 0.001 ***1.322 0.001 ***1.322 0.001
Midlands 1 1 1 1
Mid-west ***0.093 0.009 ***0.093 0.009 ***0.942 0.007 ***0.942 0.007
Northeast ***0.042 0.009 ***0.041 0.009 0.994 0.008 0.994 0.008
Northwest 0.013 0.010 0.012 0.010 ***0.946 0.008 ***0.946 0.008
Southeast ***0.051 0.009 ***0.051 0.009 ***0.930 0.007 ***0.930 0.007
South ***0.076 0.008 ***0.076 0.008 ***0.943 0.006 ***0.944 0.006
West ***0.076 0.008 ***-0.063 0.008 ***0.966 0.007 ***0.966 0.007
East ***-0.060 0.008 ***-0.060 0.008 ***1.042 0.007 ***1.042 0.007
1 month ***-0.662 0.004 ***-0.708 0.004 ***1.077 0.003 ***1.034 0.003
2 months ***0.146 0.004 ***0.133 0.004 ***1.041 0.003 ***1.020 0.003
3 months ***0.089 0.004 ***0.064 0.004 ***0.984 0.003 ***0.963 0.003
4 months ***0.164 0.004 ***0.142 0.004 ***1.027 0.003 ***1.011 0.003
5 months ***-0.027 0.004 ***-0.059 0.004 ***0.991 0.003 ***0.974 0.003
6 months ***0.220 0.004 ***0.199 0.004 ***1.064 0.003 ***1.053 0.003
7 months ***0.200 0.004 ***0.178 0.004 ***1.073 0.003 ***1.066 0.003
8 months ***0.189 0.004 ***0.167 0.004 ***1.079 0.003 ***1.073 0.003
9 months ***0.170 0.004 ***0.147 0.004 ***1.057 0.003 ***1.050 0.003
10 months ***0.143 0.004 ***0.119 0.004 ***1.024 0.003 ***1.017 0.003
11 months ***0.314 0.004 ***0.302 0.004 ***1.110 0.003 ***1.110 0.003
12 months ***-0.407 0.004 ***-0.457 0.004 ***1.061 0.003 ***1.060 0.003
13 months ***0.076 0.004 ***0.050 0.004 ***1.059 0.003 ***1.057 0.003
14 months ***0.248 0.004 ***0.238 0.004 ***1.126 0.003 ***1.128 0.003
15 months ***0.255 0.004 ***0.244 0.004 ***1.115 0.003 ***1.116 0.003
16 months ***0.237 0.004 ***0.226 0.004 ***1.054 0.003 ***1.053 0.003
17 months ***0.148 0.004 ***0.133 0.004 ***0.990 0.002 ***0.985 0.002
18 months ***0.195 0.004 ***0.182 0.004 ***1.013 0.002 ***1.010 0.003
19 months ***0.196 0.004 ***0.183 0.004 ***1.015 0.002 ***1.013 0.002
20 months ***0.108 0.004 ***0.089 0.004 ***0.977 0.002 ***0.973 0.002
21 months ***0.197 0.004 ***0.185 0.004 ***1.011 0.002 ***1.009 0.002
22 months ***0.133 0.004 ***0.119 0.004 ***0.974 0.002 ***0.970 0.002
23 months ***0.184 0.003 ***0.174 0.004 ***1.051 0.002 ***1.052 0.003
24 months ***-0.761 0.004 ***-0.824 0.004 ***0.906 0.003 ***0.898 0.003
25 months ***0.070 0.004 ***0.049 0.004 ***1.292 0.004 ***1.307 0.003
26 months ***0.153 0.003 ***0.141 0.003 ***1.064 0.002 ***1.068 0.003
27 months ***0.091 0.003 ***0.078 0.003 1.003 0.002 *1.004 0.002
28 months ***0.099 0.003 ***0.087 0.003 ***1.014 0.002 ***1.016 0.002
29 months ***0.079 0.003 ***0.068 0.003 ***1.007 0.002 ***1.010 0.002
30 months ***0.071 0.003 ***0.063 0.003 1.002 0.002 *1.004 0.002
31 months ***0.017 0.003 0.002 0.003 ***0.964 0.002 ***0.965 0.002
32 months ***0.060 0.003 ***0.050 0.003 ***0.990 0.002 ***0.992 0.002
33 months ***0.056 0.003 ***0.048 0.003 ***0.983 0.002 ***0.986 0.002
34 months ***-0.012 0.003 ***-0.018 0.003 ***0.959 0.002 ***0.960 0.002
35 months ***0.018 0.003 ***0.023 0.003 ***1.007 0.002 ***1.009 0.002
36 months 1 1 1 1
Decedent*1 month ***0.761 0.018 ***1.579 0.025
Decedent* 2 months ***0.190 0.018 ***1.355 0.020
Decedent*3months ***0.392 0.018 ***1.379 0.019
Decedent*4 months ***0.337 0.018 ***1.266 0.017
Decedent*5months ***0.548 0.018 ***1.286 0.018
Decedent*6months ***0.334 0.018 ***1.172 0.016
Decedent*7months ***0.351 0.018 ***1.126 0.015
Decedent*8 months ***0.352 0.018 ***1.101 0.015
Decedent*9months ***0.362 0.018 ***1.111 0.015
Decedent*10months ***0.382 0.018 ***1.112 0.015
Decedent*11months ***0.173 0.017 1.007 0.013
Decedent*12 month ***0.924 0.017 **1.029 0.013
Decedent*13months ***0.424 0.017 ***1.044 0.014
Decedent*14months ***0.155 0.017 **0.973 0.013
Decedent*15months ***0.161 0.016 0.981 0.012
Decedent*16months ***0.156 0.017 *1.024 0.013
Decedent*17months ***0.223 0.017 ***1.090 0.014
Decedent*18months ***0.194 0.016 ***1.052 0.013
(continued on next page)
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Table A7 (continued )
Covariates Probit GLM on positive expenditures
Basic model Interactions model Basic model Interactions model
Coeff. SE Coeff. SE Exp(Coeff.) SE Exp(Coeff.) SE
Decedent*19months ***0.203 0.016 ***1.043 0.013
Decedent*20months ***0.279 0.016 ***1.080 0.013
Decedent*21months ***0.183 0.016 **1.030 0.013
Decedent*22months ***0.211 0.016 ***1.064 0.013
Decedent*23months ***0.142 0.015 0.987 0.012
Decedent*24months ***1.154 0.016 ***1.133 0.014
Decedent*25months ***0.326 0.015 ***0.811 0.034
Decedent*26months ***0.189 0.015 ***0.927 0.011
Decedent*27months ***0.185 0.015 *0.978 0.013
Decedent*28months ***0.184 0.014 **0.970 0.012
Decedent*29months ***0.169 0.015 ***0.959 0.011
Decedent*30months ***0.122 0.015 ***0.960 0.011
Decedent*31months ***0.231 0.015 0.991 0.012
Decedent*32months ***0.149 0.014 ***0.961 0.011
Decedent*33months ***0.121 0.014 ***0.957 0.011
Decedent*34months ***0.088 0.014 0.987 0.011
Decedent*35months ***-0.067 0.015 ***0.950 0.012
Decedent*36months 1 1
Constant 0.132 0.008 1.007 0.007 1.007 0.007
Akaike Information Criteria (AIC) 11.385 11.384
Loglikelihood 37,628,213 37,625,078
n 8,341,380 8,341,380 6,609,899 6,609,899
Coefﬁcient (Coeff.), exponential (exp), Standard error (SE).
*, **, *** indicates signiﬁcance at the 90%, 95%, and 99% level, respectively.
Table A8
Expenditure projections for traditional multipliers model 1(non PTD) and model 2 (PTD).
Model Age
(years)
2011
(V)
2016
(V)
2021
(V)
2026
(V)
2031
(V)
Model 1 no PTD
Criteria: M1
70e74 223,707,467 271,337,727 330,660,614 367,286,049 414,228,508
75e79 176,330,327 195,284,968 243,280,205 300,665,815 337,531,721
80e84 119,483,924 134,718,980 154,747,088 197,884,550 248,553,951
85 and over 88,748,795 106,590,048 129,920,917 159,503,849 208,300,437
Model 2 PTD
Criteria: M1
70e74 147,312,355 177,605,682 215,455,759 238,696,807 240,125,827
75e79 125,358,156 138,028,925 170,721,661 209,872,187 212,688,641
80e84 92,537,419 103,652,134 118,216,253 149,887,099 154,161,204
85 and over 72,893,843 87,322,146 105,788,877 128,895,847 146,781,021
Model 1
no PTD
Criteria: M2
70e74 223,707,467 271,165,777 329,456,962 364,706,793 409,757,797
75e79 176,330,327 195,111,072 242,584,622 298,752,961 334,053,806
80e84 119,483,924 134,547,800 154,233,547 196,857,468 246,328,605
85 and over 88,748,795 106,590,048 129,615,938 158,741,402 206,623,054
Model 2 PTD
Criteria: M2
70e74 147,312,355 177,495,008 214,681,038 237,036,690 265,700,787
75e79 125,358,156 137,909,337 170,243,306 208,556,711 232,519,470
80e84 92,537,419 103,525,418 117,836,103 149,126,800 185,486,157
85 and over 72,893,843 87,322,146 105,562,524 128,329,965 165,018,122
Model 1 No PTD
Criteria: M3
70e74 223,707,467 270,993,826 328,253,309 362,127,537 405,974,889
75e79 176,330,327 195,111,072 241,889,039 296,840,107 331,097,577
80e84 119,483,924 134,547,800 153,720,005 195,659,205 244,445,621
85 and over 88,748,795 106,590,048 129,310,959 157,978,955 205,403,140
Model 2 PTD
Criteria: M3
70e74 147,312,355 177,384,333 213,906,317 235,376,573 263,265,949
75e79 125,358,156 137,909,337 169,764,951 207,241,235 230,486,462
80e84 92,537,419 103,525,418 117,455,954 148,239,785 184,092,275
85 and over 72,893,843 87,322,146 105,336,171 127,764,082 164,112,710
Table A9
Expenditure projections using predicted expenditure from Two part regression model
Model Age
(years)
2011
(V)
2016
(V)
2021
(V)
2026
(V)
2031
(V)
Including PTD
Criteria: M3
70e74 137,330,391 165,285,371 199,245,203 219,198,014 245,124,408
75e79 117,455,398 129,126,491 158,809,267 193,734,306 215,386,383
80e84 85,979,187 96,009,895 108,704,042 136,835,963 169,610,825
85 and over 67,743,424 81,076,455 97,648,300 118,209,443 151,352,219
Excluding PTD
Criteria: M3
70e74 214,029,071 259,269,651 314,051,881 346,460,587 388,410,943
75e79 171,576,202 189,850,591 235,367,354 288,836,861 322,170,699
80e84 118,633,336 133,589,975 152,625,696 194,266,337 242,705,450
85 and over 86,235,173 103,571,110 125,648,499 153,504,534 199,585,529
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Table A10
Ratio of Non PTD/ PTD (model 1 /model 2) expenditures
Model Age
(years)
2011 2016 2021 2026 2031
Model 1/2 70e74 1.52 1.53 1.53 1.54 1.73
Criteria: M1 75e79 1.41 1.41 1.43 1.43 1.59
Ratio: PTD/no PTD 80e84 1.29 1.30 1.31 1.32 1.61
85 and over 1.22 1.22 1.23 1.24 1.42
Model 1/2 70e74 1.52 1.53 1.53 1.54 1.54
Criteria: M2 75e79 1.41 1.41 1.42 1.43 1.44
Ratio: PTD/no PTD 80e84 1.29 1.30 1.31 1.32 1.33
85 and over 1.22 1.22 1.23 1.24 1.25
Model 1/2 70e74 1.52 1.53 1.53 1.54 1.54
Criteria: M3 75e79 1.41 1.41 1.42 1.43 1.44
Ratio: PTD/no PTD 80e84 1.29 1.30 1.31 1.32 1.33
85 and over 1.22 1.22 1.23 1.24 1.25
Predicted values from Two-part regression model 70 - 74 years 1.56 1.57 1.58 1.58 1.58
75 - 79 years 1.46 1.47 1.48 1.49 1.50
Criteria: M3 80 - 84 years 1.38 1.39 1.40 1.42 1.43
Ratio: PTD/no PTD 85 years and over 1.27 1.28 1.29 1.30 1.32
Table A11
Central Statistics Ofﬁce (CSO) Population Projection Model Criteria
Model criteria Description Details
M1 Immigration continuing to decline but returning at a high level. 19,100 per annum in 2011/2016
þ18,200 per annum in 2016/2021
þ30,000 per annum in 2021/2026
þ30,000 per annum in 2026/2031
þ30,000 per annum in 2031/2036
M2 Immigration decreasing but returning at more moderate levels. 21,600 per annum in 2011/2016
þ4700 per annum in 2016/2021
þ10,000 per annum in 2021/2026
þ10,000 per annum in 2026/2031
þ10,000 per annum in 2031/2036
M3 Immigration, remaining negative but improving. 25,100 per annum in 2011/2016
10,000 per annum in 2016/2021
5000 per annum in 2021/2026
5000 per annum in 2026/2031
5000 per annum in 2031/2036
More detail available at www.cso.ie.
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